Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

nned to do as a post-marketing study," noted Jörn Aldag, CEO of Amsterdam Molecular Therapeutics. "AMT will also continue development of other gene therapy products in the company's pipeline."

Operations

Glybera for Lipoprotein Lipase Deficiency

AMT has developed Glybera for the treatment of Lipoprotein Lipase Deficiency (LPLD), a rare and very severe disease. In patients with mutations in the LPL gene, dietary fat (triglyceride molecules) cannot be broken down and so causes chylomicrons, which carry triglycerides around the body, to accumulate in the blood. This may result in recurrent extremely painful and life-threatening episodes of pancreatitis. Pancreatitis, or inflammation of the pancreas, is a major clinical symptom of LPLD. It causes severe abdominal pain and often leads to hospitalization of patients as well as other complications such as diabetes and early atherosclerosis.

AMT submitted the Marketing Authorisation Application (MAA) for Glybera in December 2009; in June 2011 the CHMP published its opinion that Glybera is not approvable at this time.

Since originally submitting the MAA, AMT has generated significant additional data, including results from a long-term efficacy study of Glybera showing that improved chylomicron metabolism could be used as a biomarker for increased LPL activity in those patients missing the gene that produces this protein. Data showed that breakdown of chylomicrons produced after meals was greatly and significantly improved at both 14 and 52 weeks following one-time Glybera administration.

It was also shown that Glybera significantly reduces the risk of pancreatitis in LPLD patients. By reducing the incidence of pancreatitis episodes substantially, Glybera has the potential to help "normalize" the day to day lives of patients affected by this disease and prevent the often frequent trips to hospital that patients otherwise experience.

AMT has filed for re-exami
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Genaera,Corporation (Nasdaq: GENR ) today announced the ... Directors, bringing the membership total to,seven. Dr. Wotton is ... term through the Company,s 2009 Annual Meeting., "We ... Board of Directors.,He has a proven record of success ...
... Commercialize ... Novel Technology from UC Davis, BOSTON, June 30 ... university business ventures, has,established RF Biocidics, Inc., to develop and ... The newly formed RF Biocidics, Inc. is developing a ...
... PITTSBURGH, June 30 Cellumen, Inc., the Cellular,Systems ... research,collaboration with the National Center for Toxicology Research ... Administration (FDA). Under the,agreement, Cellumen will use its ... samples of known liver toxicity,compounds including both failed ...
Cached Biology Technology:Genaera Corporation Elects Paul K. Wotton to Board of Directors 2Genaera Corporation Elects Paul K. Wotton to Board of Directors 3Genaera Corporation Elects Paul K. Wotton to Board of Directors 4Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... have recovered fossils from a 60-million-year-old South American snake ... reticulated pythons seem a bit cuter and more cuddly. ... the size of the snake,s vertebrae suggest it weighed ... feet) nose to tail tip -- and that,s a ...
... the visual centers in our brain are humming with activity. ... few years that the magnitude of sense-related activity in a ... to that of one exposed to a stimulus. New research ... explaining why, even though our sense centers are working, we ...
... BETHESDA, Md. (Feb 4, 2009) - Training people to ... in the laboratory helped them to later maintain their ... from the Journal of Neurophysiology . The ... fall prevention strategies that can be generalized to a ...
Cached Biology News:At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 2At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 3Behind closed eyes 2Research model may one day 'inoculate' elderly against slip-related falls 2Research model may one day 'inoculate' elderly against slip-related falls 3
...
... cocktail is tailored to highly ... suspensions of non-human primate (Rhesus ... using the StemSep compatible 0.5 ... The CD4+ T cell content ...
... full microplate washer with a 96 needle wash ... you the best of two worlds high ... ,Separate wash and aspiration channels ensure ... precision of better than 2% CV over the ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: